The Food & Drug Administration and the National Institutes of Health launched a new program aimed at speeding innovative medical technologies to market.
The joint program involves translational science, “the shaping of basic scientific discoveries into treatments,” and regulatory science, or “the development and use of new tools, standards and approaches to more efficiently develop products and to more effectively evaluate product safety, efficacy and quality,” according to a press release.